<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132983">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02133378</url>
  </required_header>
  <id_info>
    <org_study_id>2014-01</org_study_id>
    <nct_id>NCT02133378</nct_id>
  </id_info>
  <brief_title>Prospective Clinical Trial of the Hemopatch Topic Hemostatic in Cardiac Surgery</brief_title>
  <official_title>Prospective, Randomized Clinical Trial of the Hemopatch Topic Hemostatic in Cardiac Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiochirurgia E.H.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardiochirurgia E.H.</source>
  <oversight_info>
    <authority>Italy: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A new topical hemostatic agent composed of a specifically-formulated porous collagen matrix,
      coated on one side with a thin protein bonding layer (known as NHS-PEG) has been reported to
      be extremely effective, in addition to traditional means, in terminating bleeding during
      cardiac operations with control rates as high as 97,5%. The investigators compared such
      hemostatic agent (Hemopatch; Baxter Inc, Deerfield, IL) with traditional optimized
      hemostasis routine.

      Following sample size calculation, in a prospective randomized study design, 100 patients
      will be treated with Hemopatch and 100 patients will receive traditional optimized
      hemostasis routine (comparison group).

      To make the two cohorts as comparable as possible  enrollment will be restricted to
      moderately bleeding vascular anastomosis of Dacron grafts to ascending aorta or moderately
      bleeding transversal aortotomy.

      Study endpoints are the following: rate of successful intraoperative hemostasis (identified
      by cessation of bleeding in less than 3 minutes from application) and time required for
      hemostasis; overall postoperative bleeding; rate of transfusion of blood products; rate of
      surgical revision for bleeding; postoperative morbidity; and intensive care unit stay.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of Successful Hemostasis in under 3 minutes</measure>
    <time_frame>3 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>Application of Hemopatch or traditional techniques (compression with dry or wet gauze or similar)  are considered successful if hemostasis is reached in under 3 minutes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post Operative Blood Loss</measure>
    <time_frame>6 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood loss in the first 7 hours postoperatively</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Allogeneic Blood Transfusion</measure>
    <time_frame>4 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Allogeneic Blood Transfusion in the first 4 days after surgery</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Bleeding</condition>
  <arm_group>
    <arm_group_label>Hemopatch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of Hemopatch on bleeding spot</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Traditional techniques hemostasis (dry or wet gauze compression or similar)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hemopatch</intervention_name>
    <description>Baxter Hemopatch</description>
    <arm_group_label>Hemopatch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Traditional Hemostasis Techniques (dry or wet gauze compression or similar)</intervention_name>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Surgery on Ascending Aorta with Dacron Graft or transverse Aortotomy

          -  Moderate bleeding

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Luca Weltert, MD</last_name>
    <phone>3478880617</phone>
    <email>lweltert@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>European Hospital</name>
      <address>
        <city>Rome</city>
        <zip>00151</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luca Weltert</last_name>
    </contact>
    <investigator>
      <last_name>Luca Weltert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Nasso G, Piancone F, Bonifazi R, Romano V, Visicchio G, De Filippo CM, Impiombato B, Fiore F, Bartolomucci F, Alessandrini F, Speziale G. Prospective, randomized clinical trial of the FloSeal matrix sealant in cardiac surgery. Ann Thorac Surg. 2009 Nov;88(5):1520-6. doi: 10.1016/j.athoracsur.2009.07.014.</citation>
    <PMID>19853105</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 7, 2014</lastchanged_date>
  <firstreceived_date>May 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cardiochirurgia E.H.</investigator_affiliation>
    <investigator_full_name>Luca Weltert</investigator_full_name>
    <investigator_title>Dr. Luca Weltert</investigator_title>
  </responsible_party>
  <keyword>Bleeding</keyword>
  <keyword>Hemostatic</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemostatics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
